ABSTRACT
In this study, we report two new possible susceptible genes for late-onset Alzheimer’s disease identified through an APOE-stratified genome-wide association analysis (GWAS) using East Asian samples. In the discovery phase, we performed a GWAS of Alzheimer’s disease in 2,291 Korean seniors from the Gwangju Alzheimer’s and Related Dementias (GARD) cohort study. A successive replication analysis with a Japanese sample of size 1,956 suggested three novel susceptible SNPs in two genes: LRIG1 and CACNA1A. This study demonstrates that the discovery of AD-associated variants can be accomplished in non-European ethnic groups with a more homogeneous genetic background using samples comprising fewer subjects.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the Original Technology Research Program for Brain Science of the National Research Foundation (NRF-2014M3C7A1046041 and NRF-2014M3C7A1046042), and KBRI basic research program (20-BR-03-02) funded by Koera Ministry of Science and ICT. This study was also supported by Japan Agency for Medical Research and Development (AMED) (JP18kk0205009).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the institutional review board of Chosun University Hospital, GwangJu, South Korea
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author, [K.H.L]. The data are not publicly available due to [restrictions e.g. their containing information that could compromise the privacy of research participants].
